News & Updates
Filter by Specialty:
Long-acting injectable HIV drug works for all ages
The long-acting combination of cabotegravir plus rilpivirine, administered as monthly or once-every-2-months jabs, appears to be effective in both older and younger patients living with HIV, with most maintaining virologic suppression through week 96, according to pooled data from the phase III ATLAS, FLAIR, and ATLAS-2M studies.
Long-acting injectable HIV drug works for all ages
07 Aug 2022Tenofovir in mothers plus HBIG in infants best prevent vertical HBV transmission
For mothers with hepatitis B virus (HBV) infection who are positive for both hepatitis B surface and envelope antigens, administering a combination of hepatitis B vaccine and immunoglobulin (HBIG) in their infants plus tenofovir disoproxil fumarate (TDF) in the mothers themselves appears to be the best approach for preventing vertical disease transmission, according to a study.
Tenofovir in mothers plus HBIG in infants best prevent vertical HBV transmission
07 Aug 2022RATIONALE-208 subanalyses boost tislelizumab potential for HCC
The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.
RATIONALE-208 subanalyses boost tislelizumab potential for HCC
05 Aug 2022Expectant mums’ use of dolutegravir safe for babies
Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.
Expectant mums’ use of dolutegravir safe for babies
04 Aug 2022Abiraterone-olaparib confers clinical benefit for mCRPC patients
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.